TEVA-METHYLPHENIDATE ER-C TABLET (EXTENDED-RELEASE)

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

METHYLPHENIDATE HYDROCHLORIDE

Dostupno od:

TEVA CANADA LIMITED

ATC koda:

N06BA04

INN (International ime):

METHYLPHENIDATE

Doziranje:

27MG

Farmaceutski oblik:

TABLET (EXTENDED-RELEASE)

Sastav:

METHYLPHENIDATE HYDROCHLORIDE 27MG

Administracija rute:

ORAL

Jedinice u paketu:

100/500

Tip recepta:

Schedule G (CDSA III)

Područje terapije:

Respiratory and CNS Stimulants

Proizvod sažetak:

Active ingredient group (AIG) number: 0107548007; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2023-03-21

Svojstava lijeka

_ _
PRODUCT MONOGRAPH
TEVA-METHYLPHENIDATE ER-C
(Methylphenidate Hydrochloride)
Extended-release Tablets 18 mg, 27 mg, 36 mg, and 54 mg
Teva Standard
CNS Stimulant
Teva Canada Limited
Date of Revision:
30 Novopharm Court
December 19, 2019
Toronto, Ontario
M1B 2K9
www.tevacanada.com
Submission Control No: 233639
C
_Teva-Methylphenidate ER-C_
_Page 2 of 50 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
19
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 28
PART II: SCIENTIFIC INFORMATION
....................................................................................
30
PHARMACEUTICAL INFORMATION
.................................................................................
30
CLINICAL TRIALS
.....................